Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
646 hedge funds and large institutions have $20.1B invested in Alexion Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 246 increasing their positions, 226 reducing their positions, and 80 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 12 → 16 (+4)
15% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 80
2% more funds holding
Funds holding: 636 → 646 (+10)
9% more repeat investments, than reductions
Existing positions increased: 246 | Existing positions reduced: 226
28% less capital invested
Capital invested by funds: $27.9B → $20.1B (-$7.74B)
36% less call options, than puts
Call options by funds: $176M | Put options by funds: $275M
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$192M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$184M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$163M |
| 4 |
D.E. Shaw & Co
New York
|
+$155M |
| 5 |
Ninety One (UK)
London,
United Kingdom
|
+$153M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$786M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$675M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$272M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$249M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$112M |
ALXN Hedge Fund Activity: Q3 2019 in Review
646 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2019, worth a combined $20.1B — down 28% from $27.9B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new ALXN positions and 80 closed out — a net gain of 12 holders — while 246 added to existing stakes and 226 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $192M. The largest seller was Jennison Associates, cutting an estimated $786M.
- 646 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2019, up from 636 in Q2 2019.
- Funds reported $20.1B of Alexion Pharmaceuticals stock for Q3 2019, down 28% quarter-over-quarter.
- 92 funds opened new Alexion Pharmaceuticals positions in Q3 2019 and 80 closed out, a net change of +12 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2019 was JP Morgan Chase, an estimated $192M added.
- The largest Alexion Pharmaceuticals seller in Q3 2019 was Jennison Associates, an estimated $786M sold.
Based on aggregated 13F filings for Q3 2019.